

Nicholas Wald

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7983536/publications.pdf>

Version: 2024-02-01

164
papers

7,515
citations

81900

39
h-index

58581

82
g-index

172
all docs

172
docs citations

172
times ranked

8138
citing authors

#	ARTICLE	IF	CITATIONS
1	A limitation of genetic epidemiological analysis when associations are genuinely J-shaped illustrated using a prospective study of alcohol consumption and vascular disease. <i>International Journal of Epidemiology</i> , 2022, 50, 1757-1760.	1.9	1
2	Risk or chance. <i>Journal of Medical Screening</i> , 2022, , 096914132110682.	2.3	1
3	Multi-marker risk-based screening for prostate cancer. <i>Journal of Medical Screening</i> , 2022, , 096914132210764.	2.3	0
4	Blood pressure meta-analysis highlights an implementation gap. <i>Lancet, The</i> , 2022, 399, 1379-1380.	13.7	1
5	“Risk or chance”: Authors’ response. <i>Journal of Medical Screening</i> , 2022, , 096914132210898.	2.3	0
6	Folic acid and neural tube defects: Discovery, debate and the need for policy change. <i>Journal of Medical Screening</i> , 2022, 29, 138-146.	2.3	12
7	Antenatal screening for Down’s syndrome: Revised nuchal translucency upper truncation limit due to improved precision of measurement. <i>Journal of Medical Screening</i> , 2021, 28, 88-92.	2.3	1
8	Efficacy and effectiveness. <i>Journal of Medical Screening</i> , 2021, 28, 57-58.	2.3	1
9	Lung cancer mortality reduction by LDCT screening: UKLS randomised trial results and international meta-analysis. <i>Lancet Regional Health - Europe, The</i> , 2021, 10, 100179.	5.6	82
10	Are screening practice ethics committees needed?. <i>Journal of Medical Screening</i> , 2021, 28, 096914132110392.	2.3	0
11	Mandatory UK folic acid fortification. <i>Lancet, The</i> , 2021, 398, 1961-1962.	13.7	4
12	When primary prevention replaces screening. <i>Journal of Medical Screening</i> , 2021, , 096914132110659.	2.3	0
13	Two under-recognized limitations of number needed to treat. <i>International Journal of Epidemiology</i> , 2020, 49, 359-360.	1.9	3
14	Urgent need for folic acid fortification of flour and grains: response to the 2019 UK Government’s public consultation. <i>Archives of Disease in Childhood</i> , 2020, 105, 6-9.	1.9	8
15	Conflating screening detection rates with the uptake of further testing: A potential source of confusion. <i>Journal of Medical Screening</i> , 2019, 26, 1-2.	2.3	1
16	Cost and efficacy comparison of prenatal recall and reflex DNA screening for trisomy 21, 18 and 13. <i>PLoS ONE</i> , 2019, 14, e0220053.	2.5	1
17	Randomized Crossover Trial of Phosphate-binding Medication on Serum Phosphate Levels in Patients With Aortic Stenosis. <i>Clinical Therapeutics</i> , 2019, 41, 2066-2072.e2.	2.5	3
18	A simple method to allow for guanine-cytosine amplification error in prenatal DNA screening for trisomy 18. <i>Clinica Chimica Acta</i> , 2019, 496, 13-17.	1.1	0

#	ARTICLE	IF	CITATIONS
19	The illusion of polygenic disease risk prediction. <i>Genetics in Medicine</i> , 2019, 21, 1705-1707.	2.4	110
20	Integration of childâ€‘parent screening and cascade testing for familial hypercholesterolaemia. <i>Journal of Medical Screening</i> , 2019, 26, 71-75.	2.3	19
21	Prenatal reflex DNA screening for trisomy 21, 18 and 13. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 399-401.	3.1	2
22	Prenatal reflex DNA screening for trisomies 21, 18, and 13. <i>Genetics in Medicine</i> , 2018, 20, 825-830.	2.4	24
23	Medical Screening Society membersâ€™ talks. <i>Journal of Medical Screening</i> , 2018, 25, 113-113.	2.3	0
24	Prenatal screening for Down syndrome in twin pregnancies: Estimates of screening performance based on 61 affected and 7302 unaffected twin pregnancies. <i>Prenatal Diagnosis</i> , 2018, 38, 1079-1085.	2.3	4
25	Specifying a Gold Standard for the Validation of Fetal Fraction Estimation in Prenatal Screening. <i>Clinical Chemistry</i> , 2018, 64, 1394-1399.	3.2	7
26	When Guidelines Cause Hypertension. <i>American Journal of Medicine</i> , 2018, 131, 1402-1404.	1.5	1
27	Serum marker truncation limits in first trimester antenatal screening for trisomy 18. <i>Journal of Medical Screening</i> , 2018, 25, 169-173.	2.3	2
28	Public health failure in the prevention of neural tube defects: time to abandon the tolerable upper intake level of folate. <i>Public Health Reviews</i> , 2018, 39, 2.	3.2	68
29	Response to Walker. <i>Genetics in Medicine</i> , 2018, 20, 1295-1295.	2.4	4
30	Sharing Clinical Trial Data. <i>Journal of Medical Screening</i> , 2017, 24, 57-57.	2.3	2
31	Starting the polypill: the use of a single age cut-off in males and females. <i>Journal of Medical Screening</i> , 2017, 24, 50-53.	2.3	5
32	Should a Reduction in All-Cause Mortality Be the Goal When Assessing Preventive Medical Therapies?. <i>Circulation</i> , 2017, 135, 1985-1987.	1.6	23
33	Blood pressure and cardiovascular outcomes: a closer look. <i>Lancet, The</i> , 2017, 389, 1296.	13.7	0
34	Screening and preventive medication. <i>Journal of Medical Screening</i> , 2017, 24, 169-169.	2.3	2
35	The Need to Interpret the Results of a Clinical Trial in the Context of Other Evidence. <i>American Journal of Medicine</i> , 2017, 130, 251-252.	1.5	0
36	Prenatal maternal plasma DNA screening for cystic fibrosis: A computer modelling study of screening performance. <i>F1000Research</i> , 2017, 6, 1896.	1.6	2

#	ARTICLE	IF	CITATIONS
37	Insulin dependent diabetes mellitus (IDDM) and first trimester markers in prenatal screening for Down syndrome. <i>Prenatal Diagnosis</i> , 2016, 36, 192-193.	2.3	4
38	The Reply. <i>American Journal of Medicine</i> , 2016, 129, e303.	1.5	0
39	Cost-benefit analysis of the polypill in the primary prevention of myocardial infarction and stroke. <i>European Journal of Epidemiology</i> , 2016, 31, 415-426.	5.7	22
40	The Limited Public Health Impact of "Lifestyle" Change. <i>American Journal of Medicine</i> , 2016, 129, 1236.	1.5	0
41	Interpretation of the evidence for the efficacy and safety of statin therapy. <i>Lancet</i> , The, 2016, 388, 2532-2561.	13.7	1,399
42	Child-Parent Familial Hypercholesterolemia Screening in Primary Care. <i>New England Journal of Medicine</i> , 2016, 375, 1628-1637.	27.0	250
43	Sodium and cardiovascular disease. <i>Lancet</i> , The, 2016, 388, 2111-2112.	13.7	2
44	Prenatal reflex DNA screening for Down syndrome: enhancing the screening performance of the initial first trimester test. <i>Prenatal Diagnosis</i> , 2016, 36, 328-331.	2.3	4
45	Discounting financial costs and health benefits in public health programmes. <i>Journal of Medical Screening</i> , 2016, 23, 115-115.	2.3	2
46	Antenatal reflex DNA screening for Down's syndrome using total instead of free B-hCG in the Combined test. <i>Journal of Medical Screening</i> , 2016, 23, 50-51.	2.3	0
47	Antenatal reflex DNA screening for trisomy 18 and trisomy 13 in addition to Down's syndrome. <i>Journal of Medical Screening</i> , 2016, 23, 171-174.	2.3	2
48	The NHS Health Checks programme: A better alternative. <i>Journal of Medical Screening</i> , 2016, 23, 57-58.	2.3	2
49	Sequential integrated antenatal screening for Down's syndrome, trisomy 18 and trisomy 13. <i>Journal of Medical Screening</i> , 2016, 23, 116-123.	2.3	0
50	Grapefruit Juice and Statins. <i>American Journal of Medicine</i> , 2016, 129, 26-29.	1.5	57
51	The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer. <i>Health Technology Assessment</i> , 2016, 20, 1-146.	2.8	204
52	Reflex antenatal DNA screening for Down syndrome. <i>Prenatal Diagnosis</i> , 2015, 35, 1154-1154.	2.3	9
53	Occupational Exposure to Hydrazine and Subsequent Risk of Lung Cancer: 50-Year Follow-Up. <i>PLoS ONE</i> , 2015, 10, e0138884.	2.5	13
54	Presentation of meta-analysis plots. <i>Journal of Medical Screening</i> , 2015, 22, 49-51.	2.3	10

#	ARTICLE	IF	CITATIONS
55	Antenatal screening for Down's syndrome, trisomy 18, and trisomy 13: Reporting a single screening result for all three. <i>Journal of Medical Screening</i> , 2015, 22, 100-105.	2.3	3
56	Performance of antenatal reflex DNA screening for Down's syndrome. <i>Journal of Medical Screening</i> , 2015, 22, 168-174.	2.3	12
57	Prevention of Neural Tube Defects: A Cross-Sectional Study of the Uptake of Folic Acid Supplementation in Nearly Half a Million Women. <i>PLoS ONE</i> , 2014, 9, e89354.	2.5	82
58	Quantifying the health benefits of chronic disease prevention: a fresh approach using cardiovascular disease as an example. <i>European Journal of Epidemiology</i> , 2014, 29, 605-612.	5.7	19
59	The estimation of median nuchal translucency values between 10 and 14 weeks of pregnancy. <i>Journal of Medical Screening</i> , 2014, 21, 110-112.	2.3	4
60	Glycated Hemoglobin Measurement and Prediction of Cardiovascular Disease. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1225.	7.4	179
61	Cochrane report on lowering blood pressure. <i>Journal of Medical Screening</i> , 2014, 21, 3-4.	2.3	0
62	The area under the ROC curve: Is it a valid measure of screening performance?. <i>Journal of Medical Screening</i> , 2014, 21, 220-220.	2.3	4
63	Thyroid stimulating hormone and free thyroxine in pregnancy: Expressing concentrations as multiples of the median (MoMs). <i>Clinica Chimica Acta</i> , 2014, 430, 33-37.	1.1	55
64	Refining the American guidelines for prevention of cardiovascular disease. <i>Lancet</i> , The, 2014, 383, 598.	13.7	2
65	The Triple Test. <i>Clinical Chemistry</i> , 2014, 60, 269-270.	3.2	4
66	Randomised Trial of Text Messaging on Adherence to Cardiovascular Preventive Treatment (INTERACT) <i>TJ ETQq0 0 0 rgt /Overlock 10 T</i>	2.5	84
67	Allowing for ethnic group in antenatal screening for Down's syndrome. <i>Journal of Medical Screening</i> , 2013, 20, 52-54.	2.3	4
68	Improvements in antenatal screening for Down's syndrome. <i>Journal of Medical Screening</i> , 2013, 20, 7-14.	2.3	20
69	The press, press releases, and raising unwarranted expectations. <i>Journal of Medical Screening</i> , 2013, 20, 55-56.	2.3	0
70	Detection of trisomy 18 and trisomy 13 using first and second trimester Down's syndrome screening markers. <i>Journal of Medical Screening</i> , 2013, 20, 57-65.	2.3	19
71	Incorporating DNA Sequencing into Current Prenatal Screening Practice for Down's Syndrome. <i>PLoS ONE</i> , 2013, 8, e58732.	2.5	27
72	The Canadian Recommendations on Screening for Type 2 Diabetes. <i>Journal of Medical Screening</i> , 2012, 19, 163-163.	2.3	0

#	ARTICLE	IF	CITATIONS
73	Risk Estimation Versus Screening Performance: A Comparison of Six Risk Algorithms for Cardiovascular Disease. <i>Journal of Medical Screening</i> , 2012, 19, 201-205.	2.3	20
74	The value of early second trimester PAPP-A and ADAM12 in screening for pre-eclampsia. <i>Journal of Medical Screening</i> , 2012, 19, 51-54.	2.3	13
75	Antenatal Screening for Down Syndrome Using Serum Placental Growth Factor with the Combined, Quadruple, Serum Integrated and Integrated Tests. <i>PLoS ONE</i> , 2012, 7, e46955.	2.5	13
76	Reply. <i>European Thyroid Journal</i> , 2012, 1, 134-134.	2.4	0
77	Cost-effectiveness of diagnosis of high blood pressure in primary care. <i>Lancet, The</i> , 2012, 379, 709-710.	13.7	3
78	Screening for pre-eclampsia using serum placental growth factor and endoglin with Down's syndrome Quadruple test markers. <i>Journal of Medical Screening</i> , 2012, 19, 60-67.	2.3	6
79	Adding ductus venosus blood flow as a categorical variable to the Combined and Integrated tests in Down's syndrome screening. <i>Journal of Medical Screening</i> , 2012, 19, 49-50.	2.3	5
80	Personalized medicine: hope or hype. <i>European Heart Journal</i> , 2012, 33, 1553-1554.	2.2	3
81	Randomized Polypill Crossover Trial in People Aged 50 and Over. <i>PLoS ONE</i> , 2012, 7, e41297.	2.5	128
82	Body weight reduction to avoid the excess risk of type 2 diabetes. <i>British Journal of General Practice</i> , 2012, 62, e411-e414.	1.4	10
83	Unconjugated estriol values between 14 and 22 weeks of gestation in relation to prenatal screening for Down syndrome. <i>Prenatal Diagnosis</i> , 2012, 32, 299-301.	2.3	6
84	Effect of interrupting prenatal Down syndrome screening due to a large nuchal translucency. <i>Prenatal Diagnosis</i> , 2012, 32, 655-661.	2.3	1
85	Implementation of a simple age-based strategy in the prevention of cardiovascular disease: the Polypill approach. <i>Journal of Evaluation in Clinical Practice</i> , 2012, 18, 612-615.	1.8	8
86	The Polypill in the prevention of cardiovascular disease. <i>Preventive Medicine</i> , 2011, 52, 16-17.	3.4	19
87	Community Corner: Opening the Pandora's box of prenatal genetic testing. <i>Nature Medicine</i> , 2011, 17, 250-251.	30.7	11
88	Unified prenatal screening for Down's syndrome and pre-eclampsia. <i>Clinical Biochemistry</i> , 2011, 44, 455.	1.9	1
89	Screening for cardiovascular disease: Concerns with a Norwegian proposal. <i>Journal of Medical Screening</i> , 2011, 18, 165-166.	2.3	1
90	Discounting the Value of Life. <i>Journal of Medical Screening</i> , 2011, 18, 1-1.	2.3	8

#	ARTICLE	IF	CITATIONS
91	Assessing Risk Factors as Potential Screening Tests. Archives of Internal Medicine, 2011, 171, 286.	3.8	40
92	Screening for Future Cardiovascular Disease Using Age Alone Compared with Multiple Risk Factors and Age. PLoS ONE, 2011, 6, e18742.	2.5	95
93	Prenatal screening for open neural tube defects and Down syndrome: three decades of progress. Prenatal Diagnosis, 2010, 30, 619-621.	2.3	20
94	The polypill in the primary prevention of cardiovascular disease. Fundamental and Clinical Pharmacology, 2010, 24, 29-35.	1.9	11
95	Medical screening. , 2010, , 95-108.		3
96	Medical screening. , 2010, , 94-108.		4
97	Antenatal screening for Down's syndrome using the Integrated test at two London hospitals. Journal of Medical Screening, 2009, 16, 7-10.	2.3	13
98	Inhibinâ€A concentrations between 14 and 22 weeks of gestation. Prenatal Diagnosis, 2008, 28, 360-361.	2.3	5
99	Contingent screening for Down syndrome. Prenatal Diagnosis, 2008, 28, 781-781.	2.3	1
100	Prenatal screening for serious congenital heart defects using nuchal translucency: a metaâ€analysis. Prenatal Diagnosis, 2008, 28, 1094-1104.	2.3	29
101	First trimester Down's syndrome screening marker values and cigarette smoking: new data and a meta-analysis on free ð² human chorionic gonadotrophin, pregnancy-associated plasma protein-A and nuchal translucency. Journal of Medical Screening, 2008, 15, 204-206.	2.3	19
102	Paying for publication. Journal of Medical Screening, 2007, 14, 1-1.	2.3	0
103	Should folic acid fortification be mandatory? Yes. BMJ: British Medical Journal, 2007, 334, 1252-1252.	2.3	30
104	Truncation limits for CT marker ratios in prenatal screening for Down syndrome. Prenatal Diagnosis, 2007, 27, 187-188.	2.3	1
105	Validation plots in antenatal screening for Down's syndrome. Journal of Medical Screening, 2006, 13, 166-171.	2.3	7
106	Cross-trimester marker ratios in prenatal screening for Down syndrome. Prenatal Diagnosis, 2006, 26, 514-523.	2.3	20
107	Effect on down syndrome screening performance of adjusting for marker levels in a previous pregnancy. Prenatal Diagnosis, 2006, 26, 539-544.	2.3	13
108	Screening in early pregnancy for preâ€eclampsia using down syndrome quadruple test markers. Prenatal Diagnosis, 2006, 26, 559-564.	2.3	38

#	ARTICLE	IF	CITATIONS
109	Sequential and contingent prenatal screening for Down syndrome. <i>Prenatal Diagnosis</i> , 2006, 26, 769-777.	2.3	59
110	Cross trimester marker ratios: parameter estimates valid with no inconsistency. <i>Prenatal Diagnosis</i> , 2006, 26, 994-994.	2.3	1
111	Folic acid, homocysteine, and cardiovascular disease: judging causality in the face of inconclusive trial evidence. <i>BMJ: British Medical Journal</i> , 2006, 333, 1114-1117.	2.3	178
112	Prenatal screening for Down syndrome and neural tube defects in twin pregnancies. <i>Prenatal Diagnosis</i> , 2005, 25, 740-745.	2.3	28
113	Headaches and the Treatment of Blood Pressure. <i>Circulation</i> , 2005, 112, 2301-2306.	1.6	68
114	The efficacy of combining several risk factors as a screening test. <i>Journal of Medical Screening</i> , 2005, 12, 197-201.	2.3	49
115	First-Trimester or Second-Trimester Screening, or Both, for Down's Syndrome. <i>New England Journal of Medicine</i> , 2005, 353, 2001-2011.	27.0	1,044
116	Folic Acid and the Prevention of Neural-Tube Defects. <i>New England Journal of Medicine</i> , 2004, 350, 101-103.	27.0	146
117	Reply to Professor Hook. <i>Prenatal Diagnosis</i> , 2004, 24, 1018-1018.	2.3	2
118	Response to Nicolaidis. <i>Prenatal Diagnosis</i> , 2004, 24, 834-835.	2.3	1
119	Nuchal translucency and gestational age. <i>Prenatal Diagnosis</i> , 2004, 24, 150-151.	2.3	48
120	In response to Nicolaidis. <i>Prenatal Diagnosis</i> , 2004, 24, 317-318.	2.3	1
121	Prenatal screening for Down syndrome: the problem of recurrent false-positives. <i>Prenatal Diagnosis</i> , 2004, 24, 389-392.	2.3	21
122	Correlations between nuchal translucency and serum markers in SURUSS. <i>Prenatal Diagnosis</i> , 2004, 24, 835-836.	2.3	8
123	Recurrent false-positives in AFP screening for open neural tube defects. <i>Prenatal Diagnosis</i> , 2004, 24, 1018-1019.	2.3	1
124	Combining nuchal translucency and serum markers in prenatal screening for Down syndrome in twin pregnancies. <i>Prenatal Diagnosis</i> , 2003, 23, 588-592.	2.3	79
125	Antenatal screening for Down's syndrome with the quadruple test. <i>Lancet, The</i> , 2003, 361, 835-836.	13.7	130
126	Teleoanalysis: combining data from different types of study. <i>BMJ: British Medical Journal</i> , 2003, 327, 616-618.	2.3	43

#	ARTICLE	IF	CITATIONS
127	Reply to Mulvey and Wallace. Prenatal Diagnosis, 2002, 22, 633-634.	2.3	4
128	Repeat testing in antenatal screening for Down syndrome using dimeric inhibin-A in combination with other maternal serum markers. Prenatal Diagnosis, 2001, 21, 58-61.	2.3	12
129	Randomized Trial of Folic Acid Supplementation and Serum Homocysteine Levels. Archives of Internal Medicine, 2001, 161, 695.	3.8	166
130	Down syndrome fetal loss rate in early pregnancy. Prenatal Diagnosis, 2000, 20, 685-686.	2.3	3
131	Tests using multiple markers. , 2000, , 23-58.		21
132	Issues in implementing prenatal screening for cystic fibrosis: Results of a working conference. Genetics in Medicine, 1999, 1, 129-135.	2.4	15
133	Inhibin-A regression. , 1999, 19, 893-894.		2
134	Nuchal translucency and trisomy 18. , 1999, 19, 995-996.		10
135	Nuchal translucency and trisomy 18. Prenatal Diagnosis, 1999, 19, 995-996.	2.3	2
136	Routine Ultrasound Scanning for Congenital Abnormalities. Annals of the New York Academy of Sciences, 1998, 847, 173-180.	3.8	16
137	The distribution of nuchal translucency at 10-13 weeks of pregnancy. , 1998, 18, 281-286.		48
138	The distribution of nuchal translucency at 10-13 weeks of pregnancy. Prenatal Diagnosis, 1998, 18, 281-286.	2.3	4
139	Antenatal Screening for Down's Syndrome. Journal of Medical Screening, 1997, 4, 181-246.	2.3	370
140	PRENATAL SCREENING FOR DOWN'S SYNDROME USING INHIBIN-A AS A SERUM MARKER. , 1996, 16, 143-153.		199
141	PRENATAL SCREENING FOR DOWN'S SYNDROME USING INHIBIN-A AS A SERUM MARKER. Prenatal Diagnosis, 1996, 16, 143-153.	2.3	14
142	Down's syndrome screening: Value of using free β -hCG. Prenatal Diagnosis, 1995, 15, 94-95.	2.3	1
143	Further observations in connection with couple screening for cystic fibrosis. Prenatal Diagnosis, 1995, 15, 589-590.	2.3	16
144	Risk-based prenatal screening for trisomy 18 using alpha-fetoprotein, unconjugated oestriol and human chorionic gonadotropin. Prenatal Diagnosis, 1995, 15, 713-723.	2.3	149

#	ARTICLE	IF	CITATIONS
145	UKCCCR multicentre randomised controlled trial of one and two view mammography in breast cancer screening. <i>BMJ: British Medical Journal</i> , 1995, 311, 1189-1193.	2.3	128
146	Prospective observational study to assess value of prostate specific antigen as screening test for prostate cancer. <i>BMJ: British Medical Journal</i> , 1995, 311, 1340-1343.	2.3	63
147	Mortality in relation to tar yield of cigarettes: a prospective study of four cohorts. <i>BMJ: British Medical Journal</i> , 1995, 311, 1530-1533.	2.3	65
148	First Trimester Biochemical Screening for Down's Syndrome. <i>Annals of Medicine</i> , 1994, 26, 23-29.	3.8	16
149	Value of maternal serum unconjugated oestriol measurement in prenatal screening for Down's syndrome. <i>Prenatal Diagnosis</i> , 1994, 14, 699-706.	2.3	10
150	Serum alpha-fetoprotein and neural tube defects in the first trimester of pregnancy. <i>Prenatal Diagnosis</i> , 1993, 13, 1047-1050.	2.3	18
151	Use of unconjugated oestriol in screening for Down's syndrome. <i>Prenatal Diagnosis</i> , 1993, 13, 1149-1153.	2.3	12
152	Neural tube defects and serum zinc. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 1993, 100, 746-749.	2.3	42
153	The use of free beta-hCG in antenatal screening for Down's syndrome. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 1993, 100, 550-557.	2.3	60
154	Folic Acid and the Prevention of Neural Tube Defects. <i>Annals of the New York Academy of Sciences</i> , 1993, 678, 112-129.	3.8	60
155	First-trimester amniotic fluid and extraembryonic coelomic fluid acetylcholinesterase electrophoresis. <i>Prenatal Diagnosis</i> , 1992, 12, 609-612.	2.3	9
156	Maternal serum unconjugated oestriol and human chorionic gonadotrophin levels in pregnancies with insulin-dependent diabetes: implications for screening for Down's syndrome. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 1992, 99, 51-53.	2.3	44
157	Cotinine-assisted intervention in pregnancy to reduce smoking and low birthweight delivery. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 1991, 98, 859-865.	2.3	64
158	Maternal serum unconjugated oestriol and human chorionic gonadotrophin levels in twin pregnancies: implications for screening for Down's syndrome. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 1991, 98, 905-908.	2.3	98
159	A case-control study of dietary carotene in men with lung cancer and in men with other epithelial cancers. <i>Nutrition and Cancer</i> , 1991, 15, 63-68.	2.0	63
160	Reporting the assessment of screening and diagnostic tests. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 1989, 96, 389-396.	2.3	68
161	AFP and age screening for down syndrome. <i>American Journal of Medical Genetics Part A</i> , 1988, 31, 197-209.	2.4	27
162	Cigarette consumption and serum cotinine in relation to birthweight. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 1987, 94, 678-681.	2.3	117

#	ARTICLE	IF	CITATIONS
163	Neural-tube defects and vitamins: the need for a randomized clinical trial. BJOG: an International Journal of Obstetrics and Gynaecology, 1984, 91, 516-523.	2.3	81
164	When alternatives to screening should be the priority. Journal of Medical Screening, 0, , 096914132211023.	2.3	0